Showing 1361-1370 of 1697 results for "".
- Noninvasive Vagal Nerve Stimulation for Migraine Prevention Decreases in Migraine-Associated Disability and Improves Quality of Lifehttps://practicalneurology.com/news/noninvasive-vagal-nerve-stimulation-for-migraine-prevention-decreases-in-migraine-associated-disability-and-improves-quality-of-life/2469456/In the PREMIUM 2 study (NCT03716505), individuals with migraine treated with noninvasive vagal nerve stimulation (nVNS) had significant decreases in migraine-associated disability and improvement
- Treatment with C5 Inhibitor Associated with Significant, Clinically Meaningful Improvements in Generalized Myasthenia Gravis Disease Severityhttps://practicalneurology.com/news/treatment-with-c5-inhibitor-associated-with-significant-clinically-meaningful-improvements-in-generalized-myasthenia-gravis-disease-severity/2476040/Treatment with gefurulimab (Alexion Pharmaceuticals, Boston, MA), an investigational complement C5 inhibitor, was associated with significant and clinically meaningful improvements in disease severity for adults with anti-acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG)
- Washout Period Following Dimethyl Fumarate Treatment Cessation Associated with MS Disease Activity and Relapsehttps://practicalneurology.com/news/washout-period-duration-following-dimethyl-fumarate-treatment-cessation-associated-with-ms-disease-activity-and-relapse/2470484/According to results presented at the 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), disease activity was significantly associated with the duration of the interval between cessation of dimethyl fumarate (DMF) treatment and the initiation of an alternative disease-mod
- Long-Term Use of Proton Pump Inhibitors Associated with Significantly Increased Risk of Dementiahttps://practicalneurology.com/news/long-term-use-of-proton-pump-inhibitors-associated-with-significantly-increased-risk-of-dementia/2470266/Long-term, cumulative proton pump inhibitor (PPI) usage was associated with a significantly increased risk of dementia according to study results published in Neurology. During follow up, study participants who used
- Sleep-Disordered Breathing Associated with Brain Atrophy in Amyloid-Positive, Cognitively Unimpaired Individualshttps://practicalneurology.com/news/sleep-disordered-breathing-associated-with-brain-atrophy-in-amyloid-positive-cognitively-unimpaired-individuals/2470258/Research published in Neurology has identified an association between sleep-disordered breathing (SDB), such as sleep apnea, and atrophy of the medial temporal lobe (MTL) in amyloid-positive, cognitively unimpaired i
- American Heart Association Presidential Advisory Adds Sleep as Key Metric for Cardiovascular Healthhttps://practicalneurology.com/news/american-heart-association-presidential-advisory-adds-sleep-as-key-metric-for-cardiovascular-health/2469957/In a new Presidential Advisory from the American Heart Association (AHA), sleep duration has been added as an essential component for ideal heart and brain health. The update to this advisory was prepared by a volunteer wr
- GAIN Study Tests Gum Disease-Associated Protein as Target for Disease-Modifying Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/gain-study-tests-gum-disease-associated-protein-as-target-for-disease-modifying-treatment-of-alzheimer-disease/2469650/Characteristics of the study design and population for the ongoing phase 2/3 GAIN trial (NCT03823404) of atuzaginstat (COR338; Cortexyme, South San Francisco, CA) were presented at the Alzheimer Association International Conference Jul
- Interim Data from KINECT-HD2 Study Indicates Ingrezza Treatment Leads to Sustained Long-Term Improvements in Chorea Symptoms Associated with Huntingdon Diseasehttps://practicalneurology.com/news/interim-data-from-kinect-hd2-study-indicates-ingrezza-treatment-leads-to-sustained-long-term-improvements-in-chorea-symptoms-associated-with-huntingdon-disease/2470335/Researchers reported that Ingrezza treatment was associated with long-term improvements through 50 weeks in patients with chorea symptoms associated with Huntington disease (HD). Results from this analysis of interim data from the KINECT-HD2 (NCT04400331) open-label extension (OLE) study were pre
- GLP-1RAs and SGLT2is Associated with Lower Dementia Risk in People with Type 2 Diabeteshttps://practicalneurology.com/news/glp-1ras-and-sglt2is-associated-with-lower-dementia-risk-in-people-with-type-2-diabetes/2474356/Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a significantly reduced risk of developing Alzheimer disease and related dementias (ADRD) in individuals people diagnosed with type 2 diabetes mellitus (
- Research Presented at ANA 2024 Reveals Association Between Paramagnetic Rim Lesions and Disability/Disease Progression in People with MShttps://practicalneurology.com/news/research-presented-at-ana-2024-reveals-association-between-paramagnetic-rim-lesions-and-disabilitydisease-progression-in-people-with-ms/2470577/For people with multiple sclerosis (MS), a higher number of persisting paramagnetic rim lesions (PRLs) was associated with increased odds of progression independent of relapse activity (PIRA) and confirmed disability progression (CDP), according to data presented at the 2024 annual meeting of the